Provided herein are pharmaceutical compositions (e.g., formulations) that can provide for the long-term stability of AAV vectors. Also provided herein are methods of making and using the pharmaceutical compositions. The pharmaceutical compositions provided by the present disclosure generally comprise an AAV, histidine, a stabilizing agent, a salt, and a surfactant.

Expression constructs and methods for recombinant parvovirus production are disclosed. In some embodiments, the expression construct encodes (1) adenovirus E4 and E2a proteins, (2) parvovirus proteins necessary for the production of the recombinant parvovirus, and (3) a recombinant parvovirus genome, thus allowing production of the recombinant parvovirus by transfecting a host cell with a single expression construct.

This invention relates generally to compositions for making anellovectors and uses thereof. For instance, a method herein can comprise providing a nucleic acid construct that comprises a first Anellovirus genome encoding an exogenous effector and a second Anellovirus genome or fragment thereof, arranged in tandem. In some embodiments, the nucleic acid construct results in production of an anellovector comprising an Anellovirus genetic element encoding the exogenous effector, enclosed in a proteinaceous exterior.

This invention relates generally to compositions for making anellovectors and uses thereof. For instance, the disclosure provides compositions and methods for using insect cells to produce Anellovirus proteins, e.g., ORF1.

Methods of inducing a protective immune response against respiratory syncytial virus (RSV) and against influenza virus, without inducing a severe adverse event in human subjects are described. The methods include administering to the subjects an effective amount of an adenoviral vector encoding a recombinant RSV F polypeptide that is stabilized in a pre-fusion conformation, along with an effective amount of an influenza vaccine.

This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.

This invention relates generally to anellosomes and compositions and uses thereof.

The disclosure relates to compositions and methods for promoting cardiomyocyte cytokinesis and cardiomyocyte proliferation and for use in cardiac regenerative therapy. Embodiments of the disclosure are particularly useful for promoting cytokinesis in adult cardiomyocytes. In embodiments, the disclosure relates to the expression of human cyclin A2 (CCNA2) under the control of a cardiac Troponin T (cTNT) promoter to promote cytokinesis of adult human cardiomyocytes.

Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.

Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.